AU2019240247B2 - Fc variant compositions and methods of use thereof - Google Patents

Fc variant compositions and methods of use thereof

Info

Publication number
AU2019240247B2
AU2019240247B2 AU2019240247A AU2019240247A AU2019240247B2 AU 2019240247 B2 AU2019240247 B2 AU 2019240247B2 AU 2019240247 A AU2019240247 A AU 2019240247A AU 2019240247 A AU2019240247 A AU 2019240247A AU 2019240247 B2 AU2019240247 B2 AU 2019240247B2
Authority
AU
Australia
Prior art keywords
antibody
amino acid
polypeptide
seq
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019240247A
Other languages
English (en)
Other versions
AU2019240247A1 (en
Inventor
Matthew R. CHANG
Wayne A. Marasco
Quan Karen ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2019240247A1 publication Critical patent/AU2019240247A1/en
Application granted granted Critical
Publication of AU2019240247B2 publication Critical patent/AU2019240247B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019240247A 2018-03-21 2019-03-21 Fc variant compositions and methods of use thereof Active AU2019240247B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862646053P 2018-03-21 2018-03-21
US62/646,053 2018-03-21
PCT/US2019/023382 WO2019183362A1 (en) 2018-03-21 2019-03-21 Fc variant compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026203163 Division 2019-03-21

Publications (2)

Publication Number Publication Date
AU2019240247A1 AU2019240247A1 (en) 2020-10-15
AU2019240247B2 true AU2019240247B2 (en) 2026-01-29

Family

ID=67988040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019240247A Active AU2019240247B2 (en) 2018-03-21 2019-03-21 Fc variant compositions and methods of use thereof

Country Status (5)

Country Link
US (2) US20210070860A1 (enExample)
EP (1) EP3768315A4 (enExample)
JP (2) JP7551499B2 (enExample)
AU (1) AU2019240247B2 (enExample)
WO (1) WO2019183362A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998174A1 (en) * 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
CN113061192B (zh) * 2021-04-12 2023-08-22 佰思巢(上海)生物科技有限公司 一类对pd-1受体具有高亲和力的pdl1融合蛋白及其作为t细胞抑制剂的应用
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
AU2023324669A1 (en) 2022-08-15 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
EP4572785A1 (en) 2022-08-15 2025-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013165690A1 (en) * 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209392B1 (pl) * 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
DK2516468T3 (en) * 2009-12-23 2016-05-23 Synimmune Gmbh ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
US8952132B2 (en) * 2011-02-07 2015-02-10 Research Development Foundation Engineered immunoglobulin FC polypeptides
US9028826B2 (en) * 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
TWI687439B (zh) * 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
WO2016033509A1 (en) * 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
EP3191519A1 (en) * 2014-09-12 2017-07-19 Biogen MA Inc. Humanized anti-alpha v beta 5 antibodies and uses thereof
BR112017013981A2 (pt) * 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
AU2016227632A1 (en) * 2015-03-05 2017-09-14 Ucb Biopharma Sprl Polymeric Fc proteins and methods of screening to alter their functional characteristics
KR20180002653A (ko) * 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
BR112019001262A2 (pt) * 2016-07-22 2019-05-07 Dana-Farber Cancer Institute, Inc. anticorpos para o receptor do fator de necrose de tumor induzido por glicocorticoide (gitr) e métodos de uso dos mesmos
WO2018027204A1 (en) * 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013165690A1 (en) * 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof

Also Published As

Publication number Publication date
AU2019240247A1 (en) 2020-10-15
EP3768315A4 (en) 2022-11-30
US20210070860A1 (en) 2021-03-11
WO2019183362A1 (en) 2019-09-26
JP7804715B2 (ja) 2026-01-22
EP3768315A1 (en) 2021-01-27
JP2021518411A (ja) 2021-08-02
JP2024081718A (ja) 2024-06-18
JP7551499B2 (ja) 2024-09-17
US20250066481A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
US20240336694A1 (en) Compositions and methods for augmenting antibody mediated receptor signaling
US20250066481A1 (en) Fc variant compositions and methods of use thereof
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
CN112119099A (zh) 三特异性抗原结合蛋白
KR20250137191A (ko) D-도메인 함유 폴리펩타이드 및 이의 용도
CN113614109A (zh) 双功能抗pd-1/il-7分子
JP2022504826A (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
TW201522373A (zh) 抗ｃｄ５２之抗體
KR20230018425A (ko) 항-cd200r1 항체 및 이의 사용 방법
KR20250129817A (ko) D-도메인 함유 폴리펩티드 및 그의 용도
JP2025525886A (ja) Ｃｄ２８に対する多機能性分子
WO2023138638A1 (zh) 抗tigit和pd-l1的双特异性抗原结合蛋白及其用途
EP3559033A1 (en) Humanized cxcr3 antibodies with depleting activity and methods of use thereof
KR20240116828A (ko) 이중 mhc-표적화 t 세포 관여자
WO2025072871A2 (en) ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF
WO2025049915A1 (en) Ilt2 binding agents and uses thereof
CN121219321A (zh) 与bcma特异性结合的免疫刺激性抗原结合分子
TW202509064A (zh) 靶向干擾素α融合蛋白及使用方法
CN118434768A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
HK40114235A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
HK40114510A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
TW202602924A (zh) 抗ccr8抗體之醫藥配製物
CN120322455A (zh) 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用
HK40075193A (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment